RE: FCA23 Feb 2021 01:07
Fundamentally disagree. They have got compounds, best in class etc. They even have a license albeit one that has re negotiated milestone and is sitting on it. So what's left. The missing link is a convincing commercial path. I think the next 2 months will determine sar future. The world has changed rapidly, the uk govt needs to push vaccination completion because that's all it has left. Sar is not about vaccination so it will either be dropped from any uk govt finance rea arch or it will get something. If it gets dropped then sar has nothing short and medium term. I know the well researched board will talk about best in class, dementia and 28p to 40p valuations but currently that is just pie in sky wishful thinking. The company needs to deliver on covid research grant , if it achieves that then we can ride this wave as long as we can. If we fail to get research funding then sub 1p is on cards